Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 2
2002 6
2003 2
2004 4
2005 3
2006 4
2007 7
2008 3
2009 3
2010 2
2011 1
2012 2
2013 4
2014 7
2015 4
2016 4
2017 6
2018 3
2019 2
2020 4
2021 4
2022 3
2023 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group.
El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. El Bairi K, et al. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. NPJ Breast Cancer. 2021. PMID: 34853355 Free PMC article. Review.
Treatment With Erythropoietin for Patients With Optic Neuritis: Long-term Follow-up.
Küchlin S, Ihorst G, Grotejohann B, Beisse F, Heinrich SP, Albrecht P, Ungewiss J, Wörner M, Hug MJ, Wolf S, Diem R, Lagrèze WA; TONE Study Group. Küchlin S, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Apr 24;10(4):e200067. doi: 10.1212/NXI.0000000000200067. Print 2023 Jul. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 37094997 Free PMC article.
Vision-related quality of life was similar in both treatment arms (National Eye Institute Visual Functioning Questionnaire median score [IQR]: 94.0 [88.0 to 96.9] in the EPO and 93.4 [89.5 to 97.4] in the placebo group). The rate of multiple sclerosis-free survival was 38% …
Vision-related quality of life was similar in both treatment arms (National Eye Institute Visual Functioning Questionnaire median score [IQR …
The effect of recombinant erythropoietin on long-term outcome after moderate-to-severe traumatic brain injury.
Skrifvars MB, Luethi N, Bailey M, French C, Nichol A, Trapani T, McArthur C, Arabi YM, Bendel S, Cooper DJ, Bellomo R; EPO-TBI Investigators, the ANZICS Clinical Trials Group. Skrifvars MB, et al. Intensive Care Med. 2023 Jul;49(7):831-839. doi: 10.1007/s00134-023-07141-5. Epub 2023 Jul 5. Intensive Care Med. 2023. PMID: 37405413 Free PMC article.
Similarly, no evidence of treatment heterogeneity was seen for the effect of EPO on functional outcome. CONCLUSION: EPO neither decreased overall long-term mortality nor improved functional outcome in moderate or severe TBI patients treated in the intensive care uni …
Similarly, no evidence of treatment heterogeneity was seen for the effect of EPO on functional outcome. CONCLUSION: EPO neithe …
The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy.
Hosseini SM, Boright AP, Sun L, Canty AJ, Bull SB, Klein BE, Klein R; DCCT/EDIC Research Group; Paterson AD. Hosseini SM, et al. Hum Genet. 2015 Feb;134(2):247-57. doi: 10.1007/s00439-014-1517-2. Epub 2014 Dec 7. Hum Genet. 2015. PMID: 25487307 Free PMC article. Review.
Among 55 loci previously associated with DN, three showed suggestive associations with SDR in our study without maintaining significance after correction for multiple testing. Of particular interest, rs1617640 (EPO) was not significantly associated with DR status, combined …
Among 55 loci previously associated with DN, three showed suggestive associations with SDR in our study without maintaining significance aft …
A Randomized Controlled Trial: Regenerative Effects, Efficacy and Safety of Erythropoietin in Burn and Scalding Injuries.
Günter CI, Machens HG, Ilg FP, Hapfelmeier A, Jelkmann W, Egert-Schwender S, Giri S; “EPO in Burns” Study Group; Bader A. Günter CI, et al. Front Pharmacol. 2018 Oct 31;9:951. doi: 10.3389/fphar.2018.00951. eCollection 2018. Front Pharmacol. 2018. PMID: 30429786 Free PMC article.
Adverse Events (AEs) and Severe Adverse Events (SAEs) were in expected ranges; AEs EPO: 80%, (36/45), Placebo: 77%, (30/39); SAEs EPO: 24%, (11/45), Placebo: 24%, (8/39). ...Results (SOFA score) indicate a lower morbidity of the EPO group, suggesting pro-rege …
Adverse Events (AEs) and Severe Adverse Events (SAEs) were in expected ranges; AEs EPO: 80%, (36/45), Placebo: 77%, (30/39); SAEs …
Can we improve neurological outcomes in severe traumatic brain injury? Something old (early prophylactic hypothermia) and something new (erythropoietin).
Nichol AD, Cooper DJ; POLAR Study Investigators on behalf of the ANZICS-Clinical Trials Group; EPO Study Investigators on behalf of the ANZICS-Clinical Trials Group. Nichol AD, et al. Injury. 2009 May;40(5):471-8. doi: 10.1016/j.injury.2009.01.002. Epub 2009 Apr 15. Injury. 2009. PMID: 19371869 Review.
Network based statistics reveals trophic and neuroprotective effect of early high dose erythropoetin on brain connectivity in very preterm infants.
Jakab A, Ruegger C, Bucher HU, Makki M, Huppi PS, Tuura R, Hagmann C; Swiss EPO Neuroprotection Trial Group. Jakab A, et al. Neuroimage Clin. 2019;22:101806. doi: 10.1016/j.nicl.2019.101806. Epub 2019 Apr 1. Neuroimage Clin. 2019. PMID: 30991614 Free PMC article. Clinical Trial.
While evidence supports the protective effects of erythropoetin (EPO) in preventing injury, we currently lack the complete understanding of how EPO affects the emergence and maturation of anatomical brain connectivity and function. ...Our results demonstrate a weak …
While evidence supports the protective effects of erythropoetin (EPO) in preventing injury, we currently lack the complete understand …
Relation Between Gender and Concomitant Medications With Erythropoietin-Treatment on Wound Healing in Burn Patients. Post Hoc Subgroup-Analysis of the Randomized, Placebo-Controlled Clinical Trial "EPO in Burns".
Günter CI, Ilg FP, Hapfelmeier A, Egert-Schwender S, Jelkmann W, Giri S, Bader A, Machens HG; and EPO in Burns Study Group. Günter CI, et al. Front Pharmacol. 2022 Jul 1;13:812888. doi: 10.3389/fphar.2022.812888. eCollection 2022. Front Pharmacol. 2022. PMID: 35847006 Free PMC article.
Therefore, the large, prospective, placebo-controlled, randomized, double-blind, multi-center clinical trial "EPO in Burns" was initiated to investigate the effects of EPO versus placebo treatment in severely burned patients. ...In addition, results indicated an ear …
Therefore, the large, prospective, placebo-controlled, randomized, double-blind, multi-center clinical trial "EPO in Burns" was initi …
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Kos Z, et al. NPJ Breast Cancer. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32411819 Free PMC article.
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Hudeček J, et al. NPJ Breast Cancer. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 32436923 Free PMC article. Review.
76 results